WO2018195773A1 - Utilisation d'un mutant de b7-dc dans le traitement de l'asthme - Google Patents

Utilisation d'un mutant de b7-dc dans le traitement de l'asthme Download PDF

Info

Publication number
WO2018195773A1
WO2018195773A1 PCT/CN2017/081845 CN2017081845W WO2018195773A1 WO 2018195773 A1 WO2018195773 A1 WO 2018195773A1 CN 2017081845 W CN2017081845 W CN 2017081845W WO 2018195773 A1 WO2018195773 A1 WO 2018195773A1
Authority
WO
WIPO (PCT)
Prior art keywords
rgmb
asthma
hig
mutant
cells
Prior art date
Application number
PCT/CN2017/081845
Other languages
English (en)
Inventor
Lieping Chen
Xinxin NIE
Original Assignee
Sun Yat-Sen University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Yat-Sen University filed Critical Sun Yat-Sen University
Priority to PCT/CN2017/081845 priority Critical patent/WO2018195773A1/fr
Publication of WO2018195773A1 publication Critical patent/WO2018195773A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)

Definitions

  • the present invention is related to a method for prophylaxis or treatment of asthma in a subject.
  • the instant invention also concerns use of a B7-DC mutant in the preparation of a pharmaceutical compositions for prophylaxis or treatment of asthma in a subject.
  • Asthma is a chronic small airway disorder characterized by airway obstruction, wheezing airway hyper-responsiveness and inflammation recurrently. Most of this disease arises from exposure to allergens such as pollen, house dust mites, animal dander fungi, molds, air irritants and infections.
  • allergens such as pollen, house dust mites, animal dander fungi, molds, air irritants and infections.
  • Different types of immune cells participate in the pathogenesis of asthma, including eosinophils, macrophages, T cells, neutrophils and mast cells.
  • the CD4+ T helper 2 subset (Th2) is an important element in asthma progression.
  • Th2 cells When an allergen stimulates the immune system through the airway of the lung, Th2 cells produce high levels of IL-5, IL-13 and IL-4, which subsequently promote allergen-specific IgE and airway smooth muscle mediators from mast cells.
  • IL-5 can promote eosinophil development, activation, and recruitment to the airway of the lung.
  • IL-13 is involved in airway remodeling and airway hyper-responsiveness (AHR) to promote asthma disease.
  • AHR airway hyper-responsiveness
  • T helper 1 subset however, often suppresses Th2-mediated response and ample evidence indicates that the Th1/Th2 balance are critical for asthma development.
  • the Th1 can mediate suppression of Th2 responses via the production of interferon- ⁇ (IFN- ⁇ ) and IL-12.
  • IFN- ⁇ interferon- ⁇
  • B7-DC (also called PD-L2, CD273) has been reported as a ligand for programmed death one (PD-1) , but its function in the regulation of T cell responses remains elusive. While several studies support a role for B7-DC in the suppression of T cell responses via PD-1 engagement on T cells, others have shown that B7-DC may co-stimulate T cell responses and enhance immune response. Using site-directed mutagenesis, a B7-DC variant (K113S, a replacement of lysine at positive 113 with serine) lost their binding to PD-1, but retained its function in the stimulation of T cell responses. Based on these findings, the existence of a new costimulatory receptor for B7-DC was proposed.
  • K113S a replacement of lysine at positive 113 with serine
  • RGMb repulsive guidance molecule family member b
  • RGMb a GPI-linked membrane-associated protein
  • RGMb contains an N-terminal 50 amino acid signal peptide, C-terminal 35 amino acid GPI attachment signal, RGM N-terminus domain, RGM C-terminus domain and a von Willebrand factor type-D domain in the middle of the molecule.
  • RGMb mRNA is widespread in the spinal cord, brain (midbrain, hindbrain and forebrain) , liver, kidney, optic nerve and reproductive tract.
  • RGMb is a coreceptor of BMP2/4 (bone morphogenetic protein 2 and 4, BMP2/4) to enhance Smad phosphorylation responses.
  • RGMb mRNA is also found in epithelial cells, macrophages and dendritic cells. Normal lung interstitial macrophages and alveolar epithelial cells were shown to express high levels of RGMb mRNA.
  • mAb monoclonal antibody
  • K113S a B7-DC variant with selective binding capacity to RGMb but not PD-1.
  • K113S triggers RGMb to costimulate CD4+ T cell growth with bias to the Th1 response, as evidenced by increased IFN- ⁇ production in the Th1 differentiation condition; and T cells constitutively express RGMb on their cell surface.
  • K113S treatment of mice in an experimental asthma model enhanced IFN- ⁇ production in BALF, accompanied by suppressed IL-5 and IL-13 production.
  • our results support a role for RGMb as a costimulatory molecule toward CD4+ Th1 responses.
  • a method for prophylaxis or treatment of asthma in a subject comprises administering to the subject in need thereof a therapeutically effective amount of a B7-DC mutant with an amino acid sequence as shown in SEQ ID NO. 1 or 2, or an amino acid sequence having at least 80%identity to SEQ ID NO. 1 or 2 and a K113S mutation.
  • B7-DC mutant in the preparation of a pharmaceutical composition for prophylaxis or treatment of asthma in a subject.
  • the asthma is a Th2-mediated asthma.
  • the administration is carried out intravenously.
  • the B7-DC mutant is contained in a vector, preferably a plasmid.
  • the B7-DC mutant is fused with a human IgG Fc fragment, e.g., a human IgG1 Fc fragment.
  • K113S protein interacts with RGMb in a similar affinity as wild type B7-DC. More importantly, K113S costimulates CD4+ T cell responses via RGMb and promotes Th1 polarization. RGMb was found to express on the surface of mouse T cells, macrophages, neutrophils and dendritic cells. Finally, K113S/RGMb costimulation suppresses Th2-mediated asthma and ameliorates small airway inflammation and lung pathology in an experimental mouse model.
  • FIG. 1 Binding of B7-DC variants to PD-1 or RGMb.
  • A CHO cell line transfected to overexpress mouse PD-1 (PD-1+ CHO) were stained with indicated concentrations of control Ig (Flag-hIg) , B7-DC-hIg or its variants and subsequently analyzed by flow cytometry.
  • B 293 cell line transfected to overexpress mouse RGMb (RGMb+ 293T) were stained with indicated concentrations of control Ig (Flag-hIg) , B7-DC-hIg or its variant and subsequently analyzed by flow cytometry.
  • the second antibody used for staining was mouse anti-human IgG Fc- Alexa Fluor 647 . All data are representatives of three or more independent experiments.
  • FIG. 1 The binding affinity of B7-DC and its variants to RGMb.
  • A/B Biacore analysis of the surface plasmon resonance of B7-DC-hIg (A) or K113S-hIg (B) interactions with mouse RGMb which was coated on the CM5 biosensor chip at various concentrations (3.906-500nM) .
  • C/D Biacore analysis of the surface plasmon resonance of R56S-hIg (C) or E71S-hIg (D) interactions with RGMb which was coated on the chip at various concentrations (0.1094-7 ⁇ M) .
  • E The response units of surface plasmon resonance analysis of RGMb interactions with I105A-hIg, D111S-hIg, R101S-hIg and control Flag-hIg at 10 ⁇ M.
  • F 293T cell line transfected to overexpress mouse RGMb was stained at the indicated concentrations of anti-mRGMb-biotin (second antibody SA-APC) and 1 ⁇ g B7-DC-hIg or K113S-hIg (second antibody goat anti-human Fc-PE) and subsequently analyzed by flow cytometry. All data are representatives of three or more independent experiments.
  • FIG. 3 Expression of RGMb and B7-DC on mouse myeloid and lymphoid cells.
  • A RGMb cell surface expression was examined by specific polyclonal antibody ( Minneapolis, MN) by flow cytometry analysis on alveolar macrophage (AM) , peritoneal macrophage (pM ⁇ ) , bone marrow-derived dendritic cells (BMDC, immature DC, blue line mature DC, red line) , macrophage cell line RAW264.7 and freshly isolated spleen neutrophils (PMN) , T, B and NK cells.
  • AM alveolar macrophage
  • pM ⁇ peritoneal macrophage
  • BMDC bone marrow-derived dendritic cells
  • PMN freshly isolated spleen neutrophils
  • B7-DC cell surface expression was tested by flow cytometry on alveolar macrophages (AM) , peritoneal macrophages (pM ⁇ ) , bone marrow-derived dendritic cells (BMDC in both immature and mature DC, blue and red line respectively) and macrophage cell line RAW264.7. All data are representatives of three or more experiments.
  • FIG. 4 Effect of K113S variant in OVA-induced mouse model of asthma.
  • A Sensitization and challenge protocol of OVA-induced asthma and treatment.
  • BALB/c mice were inoculated intraperitoneally (i.p. ) with 10 ⁇ g grade V OVA and 1 mg alum gel in PBS on day 0 and 5. Mice were subsequently challenged by inhalation of 1%OVA in PBS for 30 min on day 11-13.
  • Plasmids Flag-hIg and K113S-hIg
  • FIG. 5 Effect of K113S on CD4+ T cell costimulation and Th1/Th2 cytokine production.
  • A/B Purified CD4 + T cells from BALB/c mice were labeled with CFSE and stimulated under Th1 differentiation conditions (IL-2 10ng/ml, IL-12 10ng/ml, anti-IL-4 10 ⁇ g/ml) in the absence (A) or presence (B) of pM ⁇ on pre-coated plates with anti-CD3 at 2.5 ⁇ g/ml and soluble anti-CD28 at 1 ⁇ g/ml for 3 days.
  • Th1 differentiation conditions IL-2 10ng/ml, IL-12 10ng/ml, anti-IL-4 10 ⁇ g/ml
  • Intracellular IL-2, IFN- ⁇ and IL-4 were assayed by specific mAb by flow cytometry in CD4 cells from BALF upon treatment by Flag-hIg or K113S-hIg during OVA-induced asthma. On day 14 after asthma induction, cells from BALF were stimulated with PMA/ionomycin/brefeldin A for 4-6h and harvested for flow cytometry analysis.
  • D/E Intracellular IL-5 (D) and IL-13 (E) were assayed by specific mAb with flow cytometry in CD4 cells from BALF upon treatment by Flag-hIg or K113S-hIg during OVA-induced asthma. Data were representative of at least three independent experiments, 5 mice in each group. NS, not significant difference; * : p ⁇ 0.05.
  • FIG. 6 K113S-hIg protein levels in BALF and sera upon hydrodynamic injection.
  • A Flag-hIg and K113S-hIg levels in BALF at day 14 after the immunization.
  • B Flag-hIg and K113S-hIg levels in sera at the indicated days after hydrodynamic injection. The data were shown as mean ⁇ SEM and samples were obtained from 5 individual mice from each group. Data were representatives of at least three independent experiments.
  • FIG. 7 The levels of IL-4 in BALF and OVA-specific IgE in sera upon K113S treatment.
  • IL-4 levels were tested in BALF by specific ELISA and
  • OVA specific IgE was analyzed in sera from the asthma model which were treated with Flag-hIg/K113S or hIg. Mean ⁇ SEM and represent three individual experiments. NS, not significant. Data were representative from three experiments, with 5 mice in each group.
  • the terms “treat” or “treatment” refer to both therapeutic treatment and prophylactic or preventative measures, wherein the object is to prevent or slow down (lessen) an undesired physiological change or disorder, such as the progression of cancer.
  • Beneficial or desired clinical results include, but are not limited to, alleviation of symptoms, diminishment of extent of disease, stabilized (i.e., not worsening) state of disease, delay or slowing of disease progression, amelioration or palliation of the disease state, and remission (whether partial or total) , whether detectable or undetectable.
  • “Treatment” can also mean prolonging survival as compared to expected survival if not receiving treatment.
  • Those in need of treatment include those already with the condition or disorder as well as those prone to have the condition or disorder or those in which the condition or disorder is to be prevented.
  • subject or “individual” or “animal” or “patient” or “mammal, ” is meant any subject, particularly a mammalian subject, for whom diagnosis, prognosis, or therapy is desired.
  • Mammalian subjects include humans, domestic animals, farm animals, and zoo, sport, or pet animals such as dogs, cats, guinea pigs, rabbits, rats, mice, horses, cattle, cows, and so on.
  • the subject herein is preferably a human.
  • phrases such as “to a patient in need of treatment” or “asubject in need of treatment” includes subjects, such as mammalian subjects, that would benefit from administration of an polypeptide or composition of the present disclosure used, e.g., for detection, for a diagnostic procedure and/or for treatment.
  • An aspect of the disclosure provides a method for prophylaxis or treatment of asthma in a subject comprising administering to the subject in need thereof a therapeutically effective amount of a B7-DC mutant having an amino acid sequence as shown in SEQ ID NO. 1 or 2 or an amino acid sequence having at least 80%sequence identity to SEQ ID NO. 1 or 2 and a K113S mutation, or a pharmaceutical composition comprising the B7-DC mutant.
  • a B7-DC mutant having an amino acid sequence as shown in SEQ ID NO. 1 or 2 or an amino acid sequence having at least 80%sequence identity to SEQ ID NO. 1 or 2 and a K113S mutation, or a pharmaceutical composition comprising the B7-DC mutant.
  • the disclosure provides the B7-DC mutant as described above for use in a method for treating or alleviating symptoms involved with asthma.
  • the B7-DC mutant or the pharmaceutical composition is administered parenterally, e.g. intravenously, Jintramuscularly, percutaneously or intracutaneously.
  • a B7-DC mutant it may be desirable to combine a B7-DC mutant with other agents effective in the treatment of asthma.
  • the treatment of asthma may be implemented with a B7-DC mutant and other anti-asthma therapies, such as ⁇ 2 receptor agonists available in the market.
  • the methods of treating asthma prevent the progression of the asthma and/or the onset of disease caused by asthma.
  • a method for preventing the progression of asthma and/or the onset of disease caused by asthma comprises administering an effective amount of a B7-DC mutant to a subject in need thereof.
  • the methods of treating asthma prevent the onset, progression and/or recurrence of a symptom associated with asthma.
  • a method for preventing a symptom associated with asthma in a subject comprises administering an effective amount of a B7-DC mutant to a subject in need thereof.
  • An aspect of the present invention provides a pharmaceutical composition comprising a therapeutically effective amount of B7-DC mutant and a pharmaceutically acceptable carrier.
  • the pharmaceutical composition is useful for prophylaxis or treatment of asthma in a subject.
  • the B7-DC mutant may be prepared in a suitable pharmaceutically acceptable carrier or excipient.
  • carrier includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.
  • carrier includes any and all solvents, dispersion media, vehicles, coatings, diluents, antibacterial and antifungal agents, isotonic and absorption delaying agents, buffers, carrier solutions, suspensions, colloids, and the like.
  • the use of such media and agents for pharmaceutical active substances is well known in the art. Except insofar as any conventional media or agent is incompatible with the active ingredient, its use in the therapeutic compositions is contemplated. Supplementary active ingredients can also be incorporated into the compositions.
  • compositions that do not produce an allergic or similar untoward reaction when administered to a human.
  • pharmaceutically acceptable refers to molecular entities and compositions that do not produce an allergic or similar untoward reaction when administered to a human.
  • aqueous composition that contains a protein as an active ingredient is well understood in the art.
  • injectables either as liquid solutions or suspensions; solid forms suitable for solution in, or suspension in, liquid prior to injection can also be prepared.
  • mice Female BALB/c mice were purchased from and housed in a specific pathogen-free facility in the Experimental Animal Center of Sun Yat-Sen University. All mouse experiments were carried out in accordance with the Sun Yat-Sen University Laboratory Animal Center guidelines and were approved by the Institutional Animal Care and Use Committee.
  • Recombinant fusion proteins antibodies and cytokines.
  • the plasmids encoding fusion protein of mouse B7-DC-human IgG1 Fc (B7-DC-hIg) and its variants were described previously (Wang, S., et al. Molecular modeling and functional mapping of B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction. J Exp Med 197, 1083-1091 (2003) ) .
  • Recombinant proteins were produced by 293T cell transfection and purified by protein A affinity column (GE) .
  • GE protein A affinity column
  • Anti-hIg was purchased from Jackson ImmunoResearch (West Grove, PA) , His-tagged recombinant mouse RGMb and anti-murine RGMb-biotin were purchased from Streptavidin-PE was purchased from BioLegend (San Diego, CA) .
  • Anti-CD3e-PE, anti-CD4-PE, anti-CD8-PE, anti-CD11c-PE, anti-Gr1-PE, anti-B220-PE, anti-CD49b-PE, anti-F4/80-PE, anti-mB7-DC-APC, anti-IL-2-FITC, anti-IFN- ⁇ -PE, anti-IL-4-APC monoclonal antibodies (mAb) and mouse IL-4, IL-5, IL-13 ELISA kits were purchased from eBioscience (San Diego, CA) .
  • SPR Surface plasmon resonance
  • Flag-hIg, mB7-DC-hIg and variant fusion proteins were diluted in HEPES buffer at the indicated concentrations (mB7-DC-hIg and K113S-hIg from 3.9 nM to 500 nM, R56S-hIg and E71S-hIg from 109.4 nM to 7 ⁇ m, I105A-hIg, D111S-hIg, R101S-hIg and Flag-hIg at 10 ⁇ M) .
  • the proteins were injected at a flow rate of 20 ⁇ l/min for 3min, and buffer was passed over the surface for 5 min for dissociation. Data were analyzed using the Biacore T100 software.
  • mice The OVA-induced asthma in mouse model was described previously. Briefly, 6-8 weeks old BALB/c mice were immunized by i. p. injection of 10 ⁇ g OVA protein (Sigma-Aldrich) mixed to 4mg aluminum hydroxide Gel (Inject Alum, Thermo) on day 0 and day 5. Mice were challenged nasally with 1%OVA in PBS using a nebulizer (Yuwell 402AI, Jiangsu, China) for 30 min on days 11 to 13. Mice were anesthetized on day 14. Blood was collected from the inferior vena cava and sera were prepared for OVA-specific IgE detection.
  • Lungs were lavaged with 0.5ml of warm PBS via a tracheal cannula three times with a total 1 ml PBS.
  • the bronchoalveolar lavage fluids (BALFs) were centrifuged and the supernatants collected for cytokine assays (below) .
  • a coulter counter (Beckman Coulter, San Diego, CA) was used to count total number of cells.
  • the lungs were also fixed with 10%Formalin and tissue sections were stained by H/E for histological evaluation.
  • control Flag-hIg or K113S-hIg plasmid at 20 ⁇ g in 2ml volume of PBS were injected within 5-10 seconds via tail vein, as described previously.
  • Human IgG protein levels in sera and BALF upon the hydrodynamic injections were tested by specific sandwich ELISA at indicated time points (Fig. 6) .
  • Airway hyper-reactivity (AHR) assays AHR to methacholine was evaluated 24h after the last 1%OVA challenge by both invasive and non-invasive assays.
  • the invasive assay was determined by FinePointe Resistance and Compliance System (Buxco Electronics, NY) . Briefly, mice were anesthetized, and tracheotomy was performed. PBS, followed by methacholine (12.5, 25mg/ml) , was nebulized and flowed into the trachea of mice for 30 seconds. Mice respiratory flow and lung pressure was directly measured.
  • Airway resistance (R L ) was defined as the pressure driving respiration divided by flow, which was computed using Buxco FinePointe Software.
  • the non-invasive assay was determined using FinePointe for Whole Body Plethysmography System (Buxco Electronics, NY, which relies on the 4 designed chambers to connect a sensitive pressure transducer to measure pressure changes and flow inside the chamber and transmit information to the Buxco FinePointe Software.
  • the software calculates several flow-derived parameters, including respiratory rate, lung volume, peak flow and time intervals. It reported data as “enhanced pause” (Penh) .
  • Penh (PEP/PIP) x ( (Te-Tr) /Tr) .
  • Te expiratory time (s) ; Tr, relaxation time (s) ;
  • PEP peak expiratory pressure (ml/s) ;
  • PIP peak inspiratory pressure
  • mice were placed individually into each chamber and allowed to acclimate for several minutes to recording baseline periods of the chamber. After baseline measurements, increasing concentrations of methacholine in PBS (0, 3.125, 6.25, 12.5, 25, 50 mg/ml) were nebulized for 1min in the main chamber through the inlet. Then the airway responses were recorded for 5 min. The Penh was computed for each group for the increasing concentration of methacholine.
  • Th1 polarization assay in vitro For Th1 generation, CD4 + T cells were labeled with carboxyfluorescein succinimidyl ester (CFSE, Thermo Fisher Scientific, MA) at 2 ⁇ M and stimulated with anti-CD3 antibody (clone 145-2C11) at 2.5 ⁇ g/ml and the indicated fusion protein at 5 ⁇ g/ml coated on the plate in the presence of 10 ⁇ g/ml anti-IL-4 and 10ng/ml IL-12 for 3 days.
  • CFSE carboxyfluorescein succinimidyl ester
  • K113S-hIg bound RGMb+ 293T cells, similar to wild type B7-DC-hIg (Fig. 1 B) while R101S, I105A and D111S completely lost binding to RGMb.
  • R56S and E71S appear to have weak binding to RGMb at high protein concentrations.
  • B7-DC interacts with both RGMb and PD-1; while, as a new finding, the K113S selectively binds to RGMb, but not to PD-1.
  • K113S binds RGMb at a similar affinity to wild type B7-DC
  • the affinity (KD) was calculated based on Biacore T100 software from “ka” (association) and “kd” (dissociation) .
  • RGMb antibody at various concentrations up to 625 ng/ml were included in the culture to compete for B7-DC or K113S fusion protein at 1 ⁇ g/ml to bind RGMb+ 293T cells using flow cytometry. Consistent with the Biocore analysis, the RGMb antibody was slightly less efficient to compete K113S-hIg than B7-DC-hIg to bind RGMb+ 293T cells in the most of tested concentrations (Fig 2F) . Therefore, lysine at amino acid 113, while is critically involved in PD-1 binding, plays minimal role in the interaction with RGMb. Our study thus identified a highly selective RGMb ligand without PD-1 interference.
  • RGMb antibody we analyzed RGMb protein expression on various immune cells.
  • RGMb appears to constitutively express at high levels on myeloid cells, including freshly isolated alveolar macrophages (AMs) , peritoneal macrophages (pM ⁇ s) , bone marrow dendritic cells (BMDCs) and neutrophils (PMNs) and a macrophage-like cell line RAW264.7 with the highest expression on pM ⁇ (Fig. 3A) .
  • RGMb protein could also be detected in low levels on the surface of resting CD3 + , CD4 + , CD8 + T cells and B cells of splenocytes, while NK cells are negative (Fig. 3A) .
  • the expression of B7-DC was limited to bone marrow-derived dendritic cells (BMDCs) while its expression levels on AMs and RAW264.7 were minimal (Fig. 3B) , a result similar to that described previously.
  • mice were first immunized and challenged later with OVA (Fig. 4A) .
  • mice developed Th2-like inflammatory responses with heavy infiltration of eosinophils.
  • mice were injected i.v. with K113S-hIg plasmid under high pressure (hydrodynamic injection) to force plasmid expression, mainly in the liver.
  • K113S-hIg plasmid under high pressure (hydrodynamic injection) to force plasmid expression, mainly in the liver.
  • total infiltrating cell numbers in the BALF was dramatically increased upon challenge with OVA.
  • mice treated with K113S-hIg had significantly decreased total cell numbers (Fig. 4B) .
  • K113S-hIg The number of eosinophils, the primary cell type during OVA-induced asthma, was also significantly suppressed by K113S-hIg (Fig. 4B and 4C) . Histological analysis of lung showed K113S-hIg treated mice had significantly less inflammatory infiltration around small airways compared with those treated with control plasmid (Fig. 4D) .
  • Airway hypersensitivity was accessed by resistance of lung (R L ) and Penh, an index of airway hypersensitivity, in this model, as described in Materials and Methods.
  • Baseline R L had no significant differences among mice treated with the control or K113S plasmids.
  • the R L of 12.5 mg/ml methacholine challenge was decreased in K113S-hIg treated mice vs. Flag-hIg treated mice (Fig. 4E) .
  • the Penh was significantly lower in mice treated with K113S-hIg than Flag-hIg (Fig 4E) .
  • cytokines in BALF from mice with OVA-induced asthma were measured using specific ELISA.
  • K113S treatment significantly increased BALF IFN- ⁇ levels while the changes in IL-2 and IL-4 were negligible (Fig. 5C) .
  • IL-5 and IL-13 play an essential role in initiating and maintaining inflammatory responses in airways. Therefore, we also measured these cytokines in BALF in this model.
  • Mice treated with K113S-hIg plasmid had significantly decreased IL-5 and IL13, while IL-4 production was not significant (Fig. 5D-E, Fig. 7) . Allergen-specific IgE may also play a role in asthma pathogenesis.
  • B7-DC The role of B7-DC in T cell responses remains controversial because both coinhibitory and costimulatory functions were reported in various experimental systems in vitro and in vivo. In addition to interacting with the coinhibitory receptor PD-1, B7-DC was also shown to bind repulsive guidance molecule b (RGMb) . Our findings provide an explanation for contradictory data on B7-DC studies.
  • RGMb repulsive guidance molecule b
  • B7-DC In the context of constitutive expression of B7-DC by dendritic cells, the costimulatory function of B7-DC may be quickly attenuated by its PD-1 engagement, which may constitute a safeguard to prevent further expansion and over-activation of T cells. Therefore, dependent on the timing and levels of RGMb and PD-1 receptors, B7-DC may display different, and sometime opposite effects on T cell responses. While it is yet to be tested if human RGMb has similar expression pattern, and more importantly, could also be costimulated upon engagement by B7-DC, our study provides a rationale to explore this possibility.
  • Th1 response in the suppression of Th2-mediated asthma is well documented. Therefore, it is highly likely that costimulation via RGMb deviates the balance of Th1/Th2, leading to suppression of the Th2 response. It is worthwhile to mention that the effect of RGMb is somewhat unique and may not be considered as a typical “Th1-like” response.
  • IFN- ⁇ production increased significantly, there was minimal change in the levels of IL-2, another important Th1 cytokine.
  • the inhibitory effect of RGMb on the “Th2-like” response is somewhat partial, as was indicated, mainly by the suppression of IL-5 and IL-13 but not IL-4.
  • the effect of RGMb on the suppression of OVA-specific IgE is also marginal (Fig. 5) . Therefore, the role of RGMb on Th1 polarization may be unique with only a partial effect.
  • RGMb reactive oxygen species
  • RGMb KO lethal in mice, which limits further exploration of RGMb function.
  • Selective binding of K113S to RGMb but not PD-1 represents a new opportunity to conduct such studies. Development of such an agonist is also useful for potential therapeutic manipulation of human disease, including asthma.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pulmonology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne une méthode de prophylaxie ou de traitement de l'asthme chez un sujet, comprenant l'administration au sujet en ayant besoin d'une quantité thérapeutiquement efficace d'un mutant de B7-DC avec une séquence d'acides aminés telle que représentée dans SEQ ID NO. 1 ou 2, ou une séquence d'acides aminés ayant au moins 80 % d'identité avec SEQ ID NO. 1 ou 2 et une mutation K113S.
PCT/CN2017/081845 2017-04-25 2017-04-25 Utilisation d'un mutant de b7-dc dans le traitement de l'asthme WO2018195773A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/081845 WO2018195773A1 (fr) 2017-04-25 2017-04-25 Utilisation d'un mutant de b7-dc dans le traitement de l'asthme

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/081845 WO2018195773A1 (fr) 2017-04-25 2017-04-25 Utilisation d'un mutant de b7-dc dans le traitement de l'asthme

Publications (1)

Publication Number Publication Date
WO2018195773A1 true WO2018195773A1 (fr) 2018-11-01

Family

ID=63917800

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/081845 WO2018195773A1 (fr) 2017-04-25 2017-04-25 Utilisation d'un mutant de b7-dc dans le traitement de l'asthme

Country Status (1)

Country Link
WO (1) WO2018195773A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029342A2 (fr) * 2007-07-13 2009-03-05 The Johns Hopkins University Variants de b7-dc
CN102250910A (zh) * 2011-05-31 2011-11-23 苏州大学 一种人可溶性b7-dc定量检测试剂盒
WO2014022759A1 (fr) * 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Agents modulant l'activation des cellules immunitaires et procédés de leur utilisation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029342A2 (fr) * 2007-07-13 2009-03-05 The Johns Hopkins University Variants de b7-dc
CN102250910A (zh) * 2011-05-31 2011-11-23 苏州大学 一种人可溶性b7-dc定量检测试剂盒
WO2014022759A1 (fr) * 2012-08-03 2014-02-06 Dana-Farber Cancer Institute, Inc. Agents modulant l'activation des cellules immunitaires et procédés de leur utilisation

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
MATSUMOTO, K. ET AL.: "B7-DC induced by IL -13 works as a feedback regulator in the effector phase of allergic asthma", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 365, no. 1, 5 November 2007 (2007-11-05), pages 170 - 175, XP022349648 *
MATSUMOTO, K. ET AL.: "B7-DC Regulates Asthmatic Response by an IFN-gamma-Dependent Mechanism", THE JOURNAL OF IMMUNOLOGY, vol. 172, no. 4, 31 December 2004 (2004-12-31), pages 2530 - 2541, XP002491039 *
WANG, S. ET AL.: "Molecular Modeling and Functional Mapping of B7-H1 and B7-DC Uncouple Costimulatory Function from PD-1 Interaction", THE JOURNAL OF EXPERIMENTAL MEDICINE, vol. 197, no. 9, 5 May 2003 (2003-05-05), pages 1083 - 1091, XP002517347 *
ZU, Y. ET AL.: "Changs of B7 Family Costimulatory Molecules and Their Receptors Expression in Children with Asthma", J. APPL. CLIN. PEDIATR., vol. 24, no. 4, 28 February 2009 (2009-02-28), pages 271 - 273 *

Similar Documents

Publication Publication Date Title
Nie et al. B7-DC (PD-L2) costimulation of CD4+ T-helper 1 response via RGMb
US20230250164A1 (en) IL-18 Binding Protein (IL-18BP) In Inflammatory Diseases
Sugimoto et al. Interleukin 18 acts on memory T helper cells type 1 to induce airway inflammation and hyperresponsiveness in a naive host mouse
Einarsson et al. Interleukin-11: stimulation in vivo and in vitro by respiratory viruses and induction of airways hyperresponsiveness.
BR112019017001A2 (pt) composição, proteína de fusão, ácido nucleico, célula hospedeira, e, métodos para produção de um domínio de aglutinação de albumina, para preparação de uma variante de il-15, para produção de uma proteína de fusão e para inibição ou redução de um tumor em um indivíduo em necessidade do mesmo.
JP6053989B2 (ja) Ｉｌ−２１抗体
CN106554417A (zh) 抗ox40抗体和使用其的方法
Venkateshaiah et al. Regulatory effects of IL-15 on allergen-induced airway obstruction
CN107406488A (zh) 用于治疗呼吸系统疾病的新型PI3Kγ抑制剂肽
Ferreira et al. Insulin modulates the immune cell phenotype in pulmonary allergic inflammation and increases pulmonary resistance in diabetic mice
JP2018104424A (ja) 認知機能改善剤
US11149071B2 (en) Fusion protein Slit2D2(C386S)-HSA and use thereof in prevention and/or treatment of lung inflammation
JP2022501319A (ja) 抗Ｓｉｇｌｅｃ抗体、それを備える薬学的組成物及びその使用
WO2004097019A1 (fr) Anticorps humain d'interleukine-18 antihumaine, fragment de celle-ci et procede d'utilisation correspondant
WO2018195773A1 (fr) Utilisation d'un mutant de b7-dc dans le traitement de l'asthme
MX2007004374A (es) Proteina quimerica.
JPH09294585A (ja) アレルゲン遺伝子を含む組換え真核細胞プラスミドおよびアレルギー性疾患の予防および／または治療のためのその使用
Spaziano et al. Nociceptin reduces the inflammatory immune microenvironment in a conventional murine model of airway hyperresponsiveness
Chen et al. IL-21 does not involve in OVA-induced airway remodeling and chronic airway inflammation
TW202140525A (zh) Ｆｇｆ２１突變體蛋白及其融合蛋白
WO2018195772A1 (fr) Pd-1h servant de cible dans le traitement de l'asthme
JP2023532882A (ja) レット症候群の処置のためのセマフォリン４ｄ結合分子の使用
CN106924718A (zh) B7‑dc突变体在治疗哮喘中的应用
US20150225476A1 (en) Method for treating a disease or disorder of the lung by inhibition of the hedgehog pathway
US20230279086A1 (en) Suppression of uveitis by single domain antibody

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17907663

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC

122 Ep: pct application non-entry in european phase

Ref document number: 17907663

Country of ref document: EP

Kind code of ref document: A1